Clinicopathological predictors to predict sustained viral response rates in p0atients with chronic hepatitis C infection

Indian Journal of Gastroenterology

Volumn 26, Issue 6, 2007, Pages 279-282

  Nachnani, Jagdish S ^a,b   Gidwani, Raja ^a   Sadeddin, Esmat ^a   Clarkston, Wendell K ^a   Fiorella, Rusell ^a   Alba, Laura M ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CONTROLLED STUDY; FATTY LIVER; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; RACE DIFFERENCE; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; TREATMENT OUTCOME;

EID: 43049119295     PISSN: 02548860     EISSN: 02548860     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Harrison SA. Steatosis and chronic hepatitis C infection: mechanisms and significance. Clin Gastroenterol Hepatol 2005;3(10 Suppl 2):S92-S96.
2. Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol 2000;30:125-43.
3. Harrison SA, Brunt EM, Qazi RA, Oliver DA, Neuschwander-Tetri BA, Di Biscegelie AM, et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005;3:604-9.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
6. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600-9.
7. Xie Y, Xu DZ, Lu ZM, Luo KX, Jia JD, Wang YM, et al. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial. Hepatobiliary Pancreat Dis Int 2005;4:213-9.
8. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
9. Hubscher SG. Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2004;16:1107-15.
10. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
11. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic Steatohepatitis Clinical Research Network Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
12. Hu KQ, Vierling JM, Redekar AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001;8:1-18.
13. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997;26:1640-5.
14. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
15. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, et al. Virahep-C Study Group: race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007;45:80-7.
16. Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-71.
17. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003;163:218-24.
18. Bressler BL, Guindi M, Yomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44.
19. Hu KQ, Currie SL, Shen H, Cheung RC, Ho SB, Bini EJ, et al. VA HCV-001 Study Group: Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Dig Dis Sci 2007;52:570-8.
20. Simmonds P Clinical relevance of hepatitis C virus genotypes. Gut 1997;40:291-3.